87 related articles for article (PubMed ID: 1643646)
1. Restricted oncogenicity of BCR/ABL p190 in transgenic mice.
Voncken JW; Griffiths S; Greaves MF; Pattengale PK; Heisterkamp N; Groffen J
Cancer Res; 1992 Aug; 52(16):4534-9. PubMed ID: 1643646
[TBL] [Abstract][Full Text] [Related]
2. Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia.
Guo JQ; Hirsch-Ginsberg CF; Xian YM; Stass SA; Champlin RE; Giralt SA; McCredie KB; Campbell ML; Arlinghaus RB
Hematol Pathol; 1993; 7(2):91-106. PubMed ID: 8340287
[TBL] [Abstract][Full Text] [Related]
3. Model mice for BCR/ABL-positive leukemias.
Honda H; Hirai H
Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387
[TBL] [Abstract][Full Text] [Related]
4. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice.
Voncken JW; Kaartinen V; Pattengale PK; Germeraad WT; Groffen J; Heisterkamp N
Blood; 1995 Dec; 86(12):4603-11. PubMed ID: 8541551
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional activation of human LIM-HOX gene hLH-2 in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl.
Wu HK; Minden MD
Biochem Biophys Res Commun; 1997 May; 234(3):742-7. PubMed ID: 9175786
[TBL] [Abstract][Full Text] [Related]
6. Clonal characteristics of acute lymphoblastic cells derived from BCR/ABL p190 transgenic mice.
Griffiths SD; Healy LE; Ford AM; Bennett CA; Voncken JW; Heisterkamp N; Groffen J; Greaves MF
Oncogene; 1992 Jul; 7(7):1391-9. PubMed ID: 1377812
[TBL] [Abstract][Full Text] [Related]
7. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
Mishra S; Zhang B; Cunnick JM; Heisterkamp N; Groffen J
Cancer Res; 2006 May; 66(10):5387-93. PubMed ID: 16707466
[TBL] [Abstract][Full Text] [Related]
8. Establishment, characterization, and chromosomal analysis of new leukemic cell lines derived from MT/p210bcr/abl transgenic mice.
Honda H; Ohno S; Takahashi T; Takatoku M; Yazaki Y; Hirai H
Exp Hematol; 1998 Mar; 26(3):188-97. PubMed ID: 9502614
[TBL] [Abstract][Full Text] [Related]
9. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M
Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
[TBL] [Abstract][Full Text] [Related]
10. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
11. ABL oncogenes directly stimulate two distinct target cells in bone marrow from 5-fluorouracil-treated mice.
Kelliher MA; Weckstein DJ; Knott AG; Wortis HH; Rosenberg N
Oncogene; 1993 May; 8(5):1249-56. PubMed ID: 8479746
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional activation of human LIM-HOX gene, hLH-2, in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl.
Wu HK; Minden MD
Biochem Biophys Res Commun; 1997 Apr; 233(3):806-12. PubMed ID: 9168938
[TBL] [Abstract][Full Text] [Related]
13. Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene.
Snyder DS; Wu Y; McMahon R; Yu L; Rossi JJ; Forman SJ
Biol Blood Marrow Transplant; 1997 Oct; 3(4):179-86. PubMed ID: 9360779
[TBL] [Abstract][Full Text] [Related]
14. BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl.
Hemmeryckx B; Reichert A; Watanabe M; Kaartinen V; de Jong R; Pattengale PK; Groffen J; Heisterkamp N
Oncogene; 2002 May; 21(20):3225-31. PubMed ID: 12082638
[TBL] [Abstract][Full Text] [Related]
15. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
[TBL] [Abstract][Full Text] [Related]
16. Bcr/Abl P190 interaction with Spa-1, a GTPase activating protein for the small GTPase Rap1.
Yi SJ; Lee HT; Groffen J; Heisterkamp N
Int J Mol Med; 2008 Oct; 22(4):453-8. PubMed ID: 18813851
[TBL] [Abstract][Full Text] [Related]
17. The Bcr N-terminal oligomerization domain contributes to the full oncogenicity of P190 Bcr/Abl in transgenic mice.
Heisterkamp N; Voncken JW; Senadheera D; Hemmeryckx B; Gonzalez-Gomez I; Reichert A; Pattengale PK; Groffen J
Int J Mol Med; 2001 Apr; 7(4):351-7. PubMed ID: 11254872
[TBL] [Abstract][Full Text] [Related]
18. Overexpression/enhanced kinase activity of BCR/ABL and altered expression of Notch1 induced acute leukemia in p210BCR/ABL transgenic mice.
Mizuno T; Yamasaki N; Miyazaki K; Tazaki T; Koller R; Oda H; Honda ZI; Ochi M; Wolff L; Honda H
Oncogene; 2008 May; 27(24):3465-74. PubMed ID: 18193087
[TBL] [Abstract][Full Text] [Related]
19. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
Gross AW; Ren R
Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
[TBL] [Abstract][Full Text] [Related]
20. Absence of bcr/abl gene in single hemopoietic progenitors in some patients with chronic myelogenous leukemia.
Misawa M; Maeda H; Hara H; Yamamoto Y; Furuyama J
Stem Cells; 1993 Nov; 11(6):536-42. PubMed ID: 7509222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
